# US 11,896,661 B2 · Influenza virus vaccine and method of making

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,896,661 B2
- Document ID: US11896661B2
- Status: Granted
- Kind: B2
- Application number: 16/608,662
- Filed: 2018-04-27
- Published: 2020-06-18
- Granted: 2024-02-13
- Earliest claimed: 2017-04-27
- Assignees: Mississippi State University
- Applicants: Mississippi State University
- Inventors: Xiu-Feng Wan; Feng Wang
- Web page: https://patentgrep.com/patent/US11896661B2

## CPC

- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 39/12: Viral antigens
- A61P 31/14: for RNA viruses
- C07K 14/005: from viruses
- C12N 9/2402: {hydrolysing O- and S- glycosyl compounds (3.2.1)}
- C12Q 1/70: involving virus or bacteriophage {(immunoassay for viruses G01N33/56983)}
- A61K 2039/5254: {avirulent or attenuated}
- C12N 2760/16121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

A composition for increasing vaccine yields due to increased virus growth in mutation comprising a vaccine strain bearing the Y161F mutation in hemagglutinin (HA). Y161F in HA increases HA thermostability without changing its original antigenic properties and enhances its binding affinity in the vaccine production platforms used in influenza vaccine manufacturing. A method for optimizing preparation of influenza vaccine seed strains which can further lower the cost of vaccines and increase profits for the vaccine companies, and also maintain antigenic stability during vaccine deliveries.

## Claims

### Claim 1

The method of using Y161F mutation in hemagglutinin to generate seed virus of high yield for influenza vaccine development and production, comprising using site-directed mutagenesis to create mutation Y161F in hemagglutinin of influenza virus.

### Claim 2 (depends on 1)

The method of claim 1, wherein the site-directed mutagenesis is performed using forward and reverse primers with SEQ ID NOs:1 and 2, respectively.

### Claim 3 (depends on 1)

The method of claim 1, wherein the site-directed mutagenesis is performed using forward and reverse primers with SEQ ID NOs:3 and 4, respectively.

### Claim 4 (depends on 1)

The method of claim 1, wherein the influenza virus is selected from the group consisting of: H1N1, H3N2, and H3N8 virus.